A Phase 1 interventional study of HM15211 or Placebo in Obesity, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Single ascending dose of HM15211 in healthy obese subjects.
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
11,536 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's enrollment of 41 is below the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HM15211 or Placebo (single dose, subcutaneous injection)
Biological: HM15211 or Placebo
HM15211 or Placebo (single dose, subcutaneous injection)
Biological: HM15211 or Placebo
HM15211 or Placebo (single dose, subcutaneous injection)
Biological: HM15211 or Placebo
HM15211 or Placebo (single dose, subcutaneous injection)
Biological: HM15211 or Placebo
HM15211 or Placebo (single dose, subcutaneous injection)
Biological: HM15211 or Placebo
Long-acting tri-agonist
Number of Participants With Adverse Events
An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products
Time frame: 1 month
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Placebo |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 7 | 6 | 10 |
| Completed | 6 | 6 | 5 | 5 | 5 | 10 |
| Not completed | 0 | 0 | 1 | 2 | 1 | 0 |
An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products
| Participants | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 3 | 2 | 3 | 7 | 4 | 7 |
Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Active | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 2 Active | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cohort 3 Active | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 4 Active | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Cohort 5 Active | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Event | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo |
|---|---|---|---|---|---|---|
| GI disordersGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 4/7 | 4/6 | 1/10 |
| Nervous system disordersNervous system disorders | 0/6 | 1/6 | 0/6 | 4/7 | 2/6 | 2/10 |
| General disorders and administrationGeneral disorders | 2/6 | 1/6 | 1/6 | 2/7 | 1/6 | 4/10 |
| Infections and infestationsInfections and infestations | 1/6 | 0/6 | 0/6 | 0/7 | 2/6 | 0/10 |
| Musculoskeletal and connective tissueMusculoskeletal and connective tissue disorders | 1/6 | 0/6 | 2/6 | 0/7 | 1/6 | 0/10 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 0/6 | 1/6 | 0/6 | 0/7 | 1/6 | 0/10 |
| Eye disordersEye disorders | 0/6 | 0/6 | 1/6 | 0/7 | 0/6 | 0/10 |
| Renal and urinary disordersRenal and urinary disorders | 0/6 | 0/6 | 0/6 | 0/7 | 1/6 | 0/10 |
| Respiratory, thoracic and mediastinalRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/10 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 0/6 | 0/6 | 0/6 | 1/7 | 0/6 | 0/10 |
all randomized subjects (total 41)
| Age, Categorical(Participants) | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 7 | 6 | 10 | 41 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 41.0 ± 14.34 | 36.3 ± 11.78 | 54.0 ± 6.13 | 49.7 ± 11.06 | 43.8 ± 13.53 | 47.4 ± 6.55 | 45.7 ± 11.38 |
| Sex: Female, Male(Participants) | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 4 | 2 | 4 | 2 | 5 | 20 |
| Male | 3 | 2 | 4 | 3 | 4 | 5 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 1 | 3 | 4 | 4 | 18 |
| Not Hispanic or Latino | 5 | 1 | 5 | 4 | 2 | 6 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 2 | 1 | 4 | 1 | 0 | 4 | 12 |
| White | 4 | 5 | 2 | 5 | 6 | 5 | 27 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 Active | Cohort 2 Active | Cohort 3 Active | Cohort 4 Active | Cohort 5 Active | Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 7 | 6 | 10 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2018 to primary completion in Sep 2018, 5 months.
Results were first posted in May 2024, 5 years 8 months after primary completion.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited →